PHE News

PHE Authors Awarded 2017 JMCP Award for Excellence

Congratulations to PHE authors Joanna MacEwan, Jason Shafrin, and Darius Lakdawalla who along with co-authors Felicia Forma, Ainslie Hatch and Jean-Pierre Lindenmayer have been awarded the 2017 JMCP Award for Excellence! The annual award, presented at AMCP, recognizes a single article that represents the best scholarly work in managed care pharmacy.

READ MORE

Precision's Experts Are In Denver for AMCP 2017!

The AMCP 2017 Annual Meeting is here! Precision is looking forward to showing off our capabilities and experts with an impressive presence. Don't miss the chance to be there!

READ MORE

Precision's Jena in Harvard Business Review: Higher U.S. Physician Spending Does Not Lead to Better Patient Outcomes

In the latest Harvard Business Review, Precision scientific advisor Anupam Jena examines new research disputing the connection between higher physician spending and better patient outcomes.

READ MORE

Maclean and Jansen Make the Case for Evidence Synthesis in Clinical Leader

In a new article for Clinical Leader, PHE's Ross Maclean and Jeroen Jansen explain how evidence synthesis can reduce the guesswork of clinical trial design.

READ MORE

Lakdawalla and Malani Author Two-Part Series in The Conversation: The ACA, and the Way Forward

PHE's Darius Lakdawalla and co-author Anup Malani provide an ACA primer, and offer a proposal for moving reform forward in a special two-part series in The Conversation.

READ MORE

"Value of Hope" Study by PHE Authors Published in Value in Health Special Issue

The study be PHE authors Jason Shafrin, Taylor Schwartz, and John Romley is featured in a special issue of Value in Health, focusing on value framework assessments.

READ MORE

Shafrin in eyeforpharma: Value-based Pricing’s Time Has Come, and It’s Here to Stay

PHE Senior Research Economist Jason Shafrin talks prices, politics, and the problem of monopolies with eyeforpharma’s Hugh Gosling.

READ MORE

Neumann Discusses Cures Act and New FDA Draft Guidance on Communication

Provisions of the 21st Century Cures Act and new FDA draft guidance suggest greater flexibility for drug companies in the communication of the real-world drug impacts of their products.

READ MORE

PHE Team Releases New Study on Medicare Part D Price Controls

Authors Moreno, van Eijndhoven, Benner and Sullivan examine the potential impact over time of government price settings for prescription drugs.

READ MORE

Peter Neumann in New England Journal of Medicine: Cost-Effectiveness 2.0 -- Poised for a Second Act?

PHE Scientific Advisor Peter Neumann offers a new perspective on cost-effectiveness analysis in the New England Journal of Medicine.

READ MORE
 
  • Academic Insights at

    the Speed of Business

     
  • Intellectual Integrity

    Led by professors at elite research universities, we bring intellectual integrity, academic rigor, and a creative approach to the most challenging problems in heath care.

     
  • Real World Impact

    PHE recommendations have defined and changed national and international payment policies.

     
  • Unparalleled Influence

    We frequently appear in top-tier publications and media outlets-- our work reaches top decision makers and influences outcomes.

     
  • Evidence Generation and

    Commercial Excellence

    As part of Precision for Value, our academic approach to research can be linked with a tailored, commercial approach that demonstrates the value of innovative medications.

     
  • Academic Insights at

    the Speed of Business